97 related articles for article (PubMed ID: 7932812)
1. p53 gene mutation in human borderline epithelial ovarian tumors.
Wertheim I; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
J Natl Cancer Inst; 1994 Oct; 86(20):1549-51. PubMed ID: 7932812
[No Abstract] [Full Text] [Related]
2. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
Jacobs IJ; Kohler MF; Wiseman RW; Marks JR; Whitaker R; Kerns BA; Humphrey P; Berchuck A; Ponder BA; Bast RC
J Natl Cancer Inst; 1992 Dec; 84(23):1793-8. PubMed ID: 1433368
[TBL] [Abstract][Full Text] [Related]
3. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
[TBL] [Abstract][Full Text] [Related]
5. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors.
Rodabaugh KJ; Biggs RB; Qureshi JA; Barrett AJ; Welch WR; Bell DA; Berkowitz RS; Mok SC
Oncogene; 1995 Oct; 11(7):1249-54. PubMed ID: 7478544
[TBL] [Abstract][Full Text] [Related]
6. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
7. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
8. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.
Lavarino C; Pilotti S; Oggionni M; Gatti L; Perego P; Bresciani G; Pierotti MA; Scambia G; Ferrandina G; Fagotti A; Mangioni C; Lucchini V; Vecchione F; Bolis G; Scarfone G; Zunino F
J Clin Oncol; 2000 Dec; 18(23):3936-45. PubMed ID: 11099323
[TBL] [Abstract][Full Text] [Related]
9. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
10. Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors.
Tsao SW; Mok CH; Oike K; Muto M; Goodman HM; Sheets EE; Berkowitz RS; Knapp RC; Lau CC
Anticancer Res; 1991; 11(6):1975-82. PubMed ID: 1776830
[TBL] [Abstract][Full Text] [Related]
11. p53 in drug resistance in ovarian cancer.
Lavarino C; Delia D; Di Palma S; Zunino F; Pilotti S
Lancet; 1997 May; 349(9064):1556. PubMed ID: 9167490
[No Abstract] [Full Text] [Related]
12. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors.
Wertheim I; Tangir J; Muto MG; Welch WR; Berkowitz RS; Chen WY; Mok SC
Oncogene; 1996 May; 12(10):2147-53. PubMed ID: 8668340
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
Choi C; Cho S; Horikawa I; Berchuck A; Wang N; Cedrone E; Jhung SW; Lee JB; Kerr J; Chenevix-Trench G; Kim S; Barrett JC; Koi M
Genes Chromosomes Cancer; 1997 Nov; 20(3):234-42. PubMed ID: 9365830
[TBL] [Abstract][Full Text] [Related]
15. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.
Naito M; Satake M; Sakai E; Hirano Y; Tsuchida N; Kanzaki H; Ito Y; Mori T
Jpn J Cancer Res; 1992 Oct; 83(10):1030-6. PubMed ID: 1333465
[TBL] [Abstract][Full Text] [Related]
16. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas.
Edelson MI; Scherer SW; Tsui LC; Welch WR; Bell DA; Berkowitz RS; Mok SC
Oncogene; 1997 Jun; 14(24):2979-84. PubMed ID: 9205105
[TBL] [Abstract][Full Text] [Related]
17. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
18. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
19. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
20. [Alterations of p53 gene in human ovarian tumor].
Chen P; Zhang Z; Zhang Q; Wu Y
Hunan Yi Ke Da Xue Xue Bao; 1997; 22(5):401-3. PubMed ID: 10073019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
